NEW YORK (GenomeWeb News) – Aureus Pharma said today that it will participate in the Biointelligence R&D Programme, a €118.2 million ($159.8 million) European consortium focused on promoting the use of systemic modeling and simulation tools for biomedical databases.
The Paris-based company said that it could receive an estimated €3.5 million for its participation in the program, under which it will contribute knowledge management and content development.
The Biointelligence R&D Programme is being coordinated by Dassault Systèmes and involves industry participants including Sanofi-Aventis, Ipsen, Servier, Pierre Fabre, Bayer Cropscience, and public research institutes such as Inserm, Inria, Genopole, and other partners.
Aureus said that the program also will enable it to evolve its data models to integrate more complex drug and drug candidate properties, biological protocols, or regulation of physiological responses.
The content Aureus will develop for the program will be focused in areas such as oncology, nuclear receptors, proteases, inhibitors, and life sciences semantics.